Boca Raton, FL- TheStockWizards.net is a Leading Penny Stock newsletter that presents stocks that have impact news and positive technical charting indicators on the OTC BB: and Pink Sheet markets. In addition to our newsletter, TheStockWizards.net is quickly becoming the fastest growing network destination for Penny &amp Micro-Cap stocks. With our over 30 years combined experience our team of analysis analyst pride themselves on tiny cap organizations that are diamonds in the ruff.

At The Stock Wizards, we analyze everyday market activity and offer our members with our technical outlook, winning stock picks, a weekly top ten list, and day-to-day trading ideas from the Traders Corner section of our website.  We follow certain patterns and bring you break out alerts, volume spikes, breaking news, upward trends, mergers and far more.  We do all the study for you and send it straight to your inbox.

The Stock Wizards has just discovered an exciting Stem Cell Business trading under five.00 dollars per share, with an initial focus on diabetes and cardiac diseases.

PROT (OTC) Sector: Stem Cell

Proteonomix, Inc., a biotechnology organization, engages in the development of stem cell therapies primarily for the therapy of diabetes and cardiac therapy. The stem cell therapy involves introduction of healthy new stem cells to repair and replace damaged or lost cells.

PROT lately announced that they have licensed Stromal Cell Technologies for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack.  Licensed from the Cohen-McNiece Foundation, this cellular technologies was developed for patients who have suffered myocardial infarctions, commonly recognized as a heart attack.

]]>

Myocardial infarction is the interruption of blood supply to part of the heart, causing some heart cells to die. The supply of blood to the heart muscle is severely decreased or stopped. Myocardial Infarction (MI) is the leading trigger of death in the United States. According to the American Heart Association, a lot more then 1.5 million Americans suffer a myocardial infarction each year, and almost half a million die.

A preferred embodiment of the technology is:

a) Enriching exclusive cells from bone marrow samples

b) Expanding these cells making use of a proprietary patent-pending approach and

c) Harvesting the stromal cell product for possible therapeutic use.

Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging skin care cosmetics based on stem cell derivatives.

Proteoderm is the 1st organization to use a matrix of proteins originally derived from non-embryonic stem cells, Matrix NC-138, to harness the anti-aging potential of stem cells in cosmeceutical goods. Proteoderm does not use enzymes, collagen or growth elements which are the ingredients of other anti-aging cosmeceuticals and Proteoderm does not utilize embryonic stem cells as a source for its anti-aging skin care goods.

PROT — Proteonomix, Inc.

Technical Outlook

The Stock Wizards loves the share structure of PROT. With only four.two million shares outstanding, the stock could genuinely break out with any kind of volume. In addition to the share structure, TSW loves the technical setup on the chart. A breakout above the psychological .00 location could send this stock a lot greater. PROT is in the correct sector, Stem Cells. A really fascinating story indeed. This is a long-term play and TSW will be watching quite closely.

To get the full list of top10 stocks for the week please click here. http://bit.ly/caFZLZ

TheStockWizards.net has not been compensated for its profile of PROT.

Forward-Searching Statement: This press release consists of “forward-seeking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Despite the fact that the Firm believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Critical aspects that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-searching statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

TheStockWizards.net has not been compensated for any stocks featured in this write-up. TheStockWizards.net is not a registered investment advisers or broker/dealer. TheStockWizards.net makes no recommendation that the buy of securities of companies profiled in this internet site is appropriate or advisable for any individual or that an investment such securities will be profitable. In common, given the nature of the companies profiled and the lack of an active trading industry their securities, investing in such securities is highly speculative and carries a high degree of risk.